Updates are available Correction dated 2023-02-21
Click to view Correction: https://doi.org/10.1136/svn-2021-001480corr1
-
Authors
Pan, Yuesong https://orcid.org/0000-0003-3082-6789
Meng, Xia
Chen, Weiqi https://orcid.org/0000-0002-2551-9314
Jing, Jing https://orcid.org/0000-0001-9822-5758
Lin, Jinxi
Jiang, Yong
Johnston, S Claiborne https://orcid.org/0000-0002-2912-0714
Bath, Philip M
Dong, Qiang
Xu, An-Ding https://orcid.org/0000-0003-3154-0985
Li, Hao https://orcid.org/0000-0002-8591-4105
Wang, Yongjun
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03871517 at ClinicalTrials.govDocuments that mention this clinical trial
Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial
https://doi.org/10.1136/svn-2021-001480
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81870905)
National Natural Science Foundation of China (U20A20358)
Hangzhou Zhongmei Huadong Pharmaceutical Co,Ltd (no award/grant number)
Capital’s Funds for Health Improvement and Research (2020-1-2041)
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2019-I2M-5-029)
- License Information
